1. Sophie Compagnon, Melodie Debacker, Gaelle Datchoua, Catherine Lucas
IPSEN
Sophie Compagnon, Melodie Debacker,
Gaelle Datchoua, Catherine Lucas

2. INTRODUCTION

3. About IPSEN Specialized world pharmaceutical group
More than 20 products marketed in the world
Originally, French independent company
Headed by Beaufour Family
Third independent pharmaceutical firm in France (sales)
Ipsen est un groupe pharmaceutique mondial spécialisé, tourné vers l’innovation, qui commercialise actuellement plus de 20 médicaments et rassemble près de collaborateurs dans le monde. Sa stratégie de développement repose sur une complémentarité entre les activités de médecine de spécialité, moteurs de sa croissance, dans les domaines thérapeutiques qu’il cible (oncologie, endocrinologie, neurologie et hématologie), et les produits de médecine générale qui contribuent notamment au financement de sa recherche. La localisation de ses quatre centres de Recherche et Développement (Paris, Boston, Barcelone, Londres) et sa plate-forme d’ingénierie des peptides et des protéines lui permettent d’être en relation avec les meilleures équipes universitaires et d’accéder à un personnel de grande qualité. Plus de 800 personnes sont affectées aux activités de R&D, avec pour mission la découverte et le développement de médicaments innovants au service des patients. Cette stratégie est également soutenue par une politique active de partenariats. En 2008, les dépenses de R&D ont atteint environ 183 millions d’euros, soit près de 19% du chiffre d’affaires consolidé, qui s’est élevé à 971 millions d’euros. Le produit des activités ordinaires a dépassé 1 milliard d’euros au terme du même exercice. Les actions Ipsen sont négociées sur le compartiment A d’Euronext Paris (mnémonique : IPN, code ISIN : FR ). Ipsen est membre du SRD (« Service de Règlement Différé ») et fait partie du SBF 120. Le site Internet d'Ipsen est

4. five major actors in the French pharmaceutical industry
G5 pharma
Ipsen
Pierre fabre
Sanofi aventis
Servier
LFB
1 032 M€
1 800 M€ M€
3 600 M€
352,4M€
five major actors in the French pharmaceutical industry
Motor of economic growth

5. Key figures IPSEN workforce CA (EN MILLIONS €) CA (EN MILLIONS €)
+ 6,4%
+ 5,5%
R&D INVESTMENT (in M€)
CA / employee
19,1%
2009: 197.3
2009 : €
18,8%
+ ratio important,
+ value added for job
2008 : €
20,1%
2007 : €
20,7%
Global average : %

6. Key figures
Sales by therapeutic area 2006

7. IPSEN sites in Europe Research centers: France, Spain, England
Industrial sites :
France, Swizerland, Ireland, England, Spain
Commercial presence :
Other European country

8. Other IPSEN sites
US : research, industrial site and commercial presence
South America : commercial
presence
China : industrial site and commercial presence
Rest of Asia : commercial presence

9. Key figures Sales by geographical area 2006
Five major western european countries 53,7%
France 31,3%
Italie 7%
Spain 5,7%
Germany 5,5%
UK 4,1%
Other european countries 22,7%
North of America 4,4%
Rest of the world 19,2%

10. BACKGROUND

11. Beaufour Laboratories
IPSEN background
Beaufour Laboratories
Founded by Dr Henri Beaufour (pharmacist) in Dreux
1929
Launch of Romarène®
digestive disorders
Launch of Citrate de bétaïne® Beaufour
dyspepsia
1954
Integration of Henri’s sons, Gerard and Albert, in Beaufour Laboratories
Launch of Actapulgite®
antacid, gastric demulcent and anti-diarrhoeal
1963

12. 70’s ’s
IPSEN background
Start marketing products of natural origin.
1970
« IPSEN » creation
Subsidiary company of « Beaufour Laboratories »
= Institut des Produits de Synthèse et d’Extraction Naturelle
Gingko biloba
Primary care

13. Start marketing products of natural origin.
70’s ’s
IPSEN background
Start marketing products of natural origin.
1972
Ginkor®
Indications: Cardiovascular
chronic venous insufficiency
acute haemorrhoid episodes
superficial phlebitis
Active substances:
Ginkgo biloba extract
Heptaminol chlorhydrate
Troxérutine
1987: Ginkor Procto®
1988: Ginkor Fort®
Primary care

14. Start marketing products of natural origin.
70’s ’s
IPSEN background
Start marketing products of natural origin.
1972
Tanakan®
Indications: Cognitive disorders
Age-related cognitive disorders (excepted Alzheimer’s disease)
Anti-ischemic (atreritis, Raynaud’s phenomenon)
cochleovestibular disorders
Active substances:
EGb 761® (Ginkgo biloba standardized extract)
Primary care

15. Start marketing products of natural origin.
70’s ’s
IPSEN background
Start marketing products of natural origin.
Smecta®
1977
Active substances:
diosmectite (clay)
Indications: Gastroenterology
Digestive coating (pain of œsopagus, stomach, duodenum and colon)
Acute and chronic diarrhea
1980
Bedelix®
Active substances:
montmorillonite beidellitique (clay)
Indications: Gastroenterology
Digestive coating
Symptomatic treatment of functionnal colopathies
Primary care

16. 90’s 90’s IPSEN background Forlax® 1996 Primary care
Active substances:
Macrogol 4000 (polyethylène glycol 4000)
Ce médicament contient un laxatif osmotique. (Il attire l'eau dans l'intestin et augmente le volume des selles.)
Il est utilisé dans le traitement symptomatique de la constipation.
Indications: Gastrointestinal
constipation (adults and children)
Primary care

17. Start in research Albert beaufour : biotechnology research
Biomeasure Boston
A. Beaufour research institute : peptide
focused engineering
Research relations with
american universities.
1976

18. Interest in specialized therapies
80’s ’s
IPSEN background
Interest in specialized therapies
1980
Partnership with
International development
Launch of Decapeptyl ®(1986)
Active substances:
triptoreline (GnRH agonist)
Indications: Oncology
Prostate cancer
Uterin fibroids
Endometriosis
Early-onset puberty
Female infertility
Decapeptyl® 1mois (1995)
Decapeptyl® 3mois (1996)
Decapeptyl® 6mois (2009, november)
Targeted therapy

19. Interest in specialized therapies
90’s ’s
IPSEN background
Interest in specialized therapies
Dysport®
1994
Purchase of KEYWOOD (UK)
Active substances:
botilium neurotoxin,type A toxin-haemagglutinin complex.
Inhibition de la sécrétion d’acétylcholine au niveau de la jonction neuromusculaire -> réduction des spasmes musculaires
Etats-unis: depuis 2009 (avril pr esthétique et octobre pour thérapeutique)
Blepharospasme = Affection consistant en des contractions involontaires des muscles des paupières (fermeture des paupières de façon répétitive et incontrôlée) dont on ne connaît pas la cause.
Le blépharospasme peut apparaître au cours de certaines affections de l'œil ou de la paupière ou après une paralysie faciale périphérique par atteinte du nerf facial. Il fait également partie d'une forme de la maladie de Gilles de la Tourette, qui associe des tics violents accompagnés de coprolalie, (mots orduriers, insultes, etc...) et d'une écholalie (répétition de mots entendus).
Rides glabellaires -> Medicis pour USA Canada Japon
Galderma pour Russie Europe de l’est UE Asie centrale Liban Israël
> 75 countries
Indications: Neuromuscular
hemifacial spasticity
Cervical dystonia
blepharospasm
(glabellaires wrinkles)
Targeted therapy

20. 90’s 90’s IPSEN background Somatuline® 1995 Targeted therapy
Interest in specialized therapies
1995
Somatuline®
Active substance:
Lanréotide = an octapeptide somatostatin analog
Inhibition of Insulin-like growth factor-1 (IGF-1) and growth hormone (GH).
Indications: Endocrinology
Acromegaly
Neuroendocrine tumours
Attention: issu de R&D Ipsen mais développé et mis sur marché en relation avec les universités américaines.
Somatuline Depot ®
1st product from IPSEN R&D approved by the FDA and
available at international level
Targeted therapy

21. 90’s 90’s IPSEN background Family business
1996
Family business
Disagreements beetwen Albert and Gerard, at last Albert bought Gerard’s parts (50%)
Still an independent family company
Progressively, Stephane Francois, son-in-law of Albert, has more importance.
Synthelabo veut racheter mais Gerard ok mais pas Albert. A la 2eme tentative, gerard vend ses parts a Albert qui veut absolument rester independant.
En 1998, PAI LBO Fund, Paribas (aujourd’hui BNP Paribas), CDC Participations et la famille Schwabe ont pris une participation significative dans le capital de la société Mayroy, holding de contrôle du Groupe.

22. 90’s ’s
IPSEN background
2001
Death of Albert. Stephane Francois is renowned CEO, but Anne and Henri Beaufour don’t agree with that. Stephane Francois is fired.
Belingard biomerieux-pierre fabre DG
2002
Welcome to Jean-Luc Bélingard !

23. New team J.L Bélingard Chairman and Chief Executive Offi cer.
Delegate General and spokesman for G5
, he was a member of the
Executive Board and CEO of BioMérieux-Pierre Fabre.
Claire Giraut
2003: Chief
Financial Offi cer
member of the Executive
Board of the Technip Group
Eric Drapé
Executive Vice-President, Manufacturing and Supply Organisation.
Senior Vice President of the company’s Diabetes Finished Products at Novo Nordisk
Jacques-Pierre Moreau
Executive Vice-President, Chief Scientifi c Offi cer
founded Biomeasure Incorporated,
based near Boston
Frédéric Babin
Executive Vice-President, Human Resources
Master of Business Law
Christophe Jean
Group Vice-President
Operations
Chairman and CEO of Pierre Fabre Médicaments.
Anne Beaufour
Director
bachelor’s degree in geology.
director of the Company since 1998.
Henri Beaufour
Director
Bachelor of arts degree.
Since 2003,manager of Camilia Holding (LXB)

24. New boss.... New strategy Optimize its primary care portfolio1
Optimize its primary care portfolio
Geographic expansion
Focus on targeted therapeutic areas 2 3

25. Optimize its primary care portfolio1
Optimize its primary care portfolio
Life Cycle Management to develop new indications or confirm the medical benefits of selected products
In-licensing of new medicines to sustain Ipsen’s primary care franchise
Cash cow
R & D $
$ $

26. Optimize its primary care portfolio1
Optimize its primary care portfolio
Life cycle Management
Tanakan®
Principal indication: Cognitive disorders
Age-related cognitive disorders (excepted Alzheimer’s disease)
35%
35%
15%
Reimbursement
+ Price cut: -15%
1972
2007
April 2010
Risque de déremboursement.
120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints.
Phase IIIb/IV Study in Elderly Over 70
This study assesses the effectiveness
of EGb 761®, in the prevention of
Alzheimer’s disease in patients
over 70 presenting a spontaneous
memory complaint.
The 2,800 patients were recruited
by September 2004 and their
treatment is due to continue for
five years
IPSEN intention: obtain AMM for Alzheimer’s disease indication
GuidAge study, for 5years (beginning :2006)
Efficacy and Tolerance of EGb 761®
A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled.

27. Optimize its primary care portfolio1
Optimize its primary care portfolio
Life cycle Management
Ginkor Fort®
35%
15% 0%
Reimbursement
+ Price cut: -15%
1972
2006
2008
2005
2007
Turnover decrease
39.7%
Risque de déremboursement.
120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints.
Phase IIIb/IV Study in Elderly Over 70
Marketing authorizations in France, Andorra and Monaco relinquished to in august 2007

28. Optimize its primary care portfolio1
Optimize its primary care portfolio
Life cycle Management
Smecta®
Bad reputation: taste
2008:
new clinical results were released
at international congresses
orange vanilla flavour
new packaging
trend of natural products
INTERNATIONAL EXPANSION
Smecta® se développe à l’international, en particulier en Chine, grâce à un système de distribution performant couvrant l’ensemble du territoire et au développement d’une activité scientifique autour des pathologies auxquelles il apporte une solution. la Chine est devenue le premier marché
mondial pour Smecta®.
China:
1st global market
SMECTA SALES UP BY 4,8% in 2008

29. Optimize its primary care portfolio1
Optimize its primary care portfolio
In-licensing of new medicines
Co-promotion agreements
Hypertension
2003
Nisis® and Nisisco ®
France
2009
Exforge®
Non steroidal anti-inflammatory drug
France
2006
Artotec®
Christophe Jean, Vice-Président Exécutif, Opérations du Groupe Ipsen a déclaré : « Après
le succès obtenus avec Nisis® et Nisisco®, nous sommes heureux d’étendre notre
collaboration avec Novartis Pharma, et d’être ainsi en mesure de proposer aux patients et
prescripteurs un produit à forte valeur ajoutée dans le domaine cardiovasculaire, une priorité
de santé publique. » Christophe Jean a ajouté : « Ce partenariat devrait permettre de mettre
à disposition de ce nouveau produit la force commerciale existante du Groupe en France,
conformément à sa stratégie d’optimisation de sa franchise de médecine générale ».
Ipsen (Euronext : FR ; IPN) et MSD annoncent aujourd'hui la conclusion d'un accord de co-marketing selon lequel MSD concède à Ipsen les droits d'exploitation en France d'Adrovance™, une association fixe d'alendronate monosodique et de colécalciférol (vitamine D3).
Aux termes du contrat, MSD fournira le médicament à Ipsen qui en assurera le marketing et la commercialisation en France
Post-menopausal osteoporosis
France
2007
Adrovance®
Hyperuricemia
Europe
2008
Adenuric ®

30. New boss.... New strategy Optimize its primary care portfolio1
Optimize its primary care portfolio
Geographic expansion
Focus on targeted therapeutic areas 2 3

31. Decrease reimbursement, generics2
Geographic expansion
Country
% variation
France
- 3,2%
Spain
2,3%
Italia
3,3%
Germany
5,3% UK
- 1,1%
Major werstern european countries
- 0,9%
Other european countries
- 0,8%
North of America
307,1%
Rest of the world (BRIC)
20,8%
Decrease reimbursement, generics
Big progression

32. Example of partnership with Inspiration2
Example of partnership with Inspiration
mission: revolutionize treatment for hemophilia
Wide portfolio in hemophilia and haemorrhage
OBI-1 : porcine FVIII treatment of hemophilia A
Reminder: Hemophilia A = deficit in FVIII controlled by injections of human FVIII ( 2 – 3t/ week)
Pb: 1/3 of cases, immune reaction (Ac anti human FVIII) preventing reinjection of human FVIII
So OBI-1 : porcine origin low cross-reactivity to Ac anti hFVIII
therapeutic benefit for these patients
IPSEN ambition: engage in a niche sector
founded in 2004

33. Example of partnership with Inspiration2
OBI-1: porcine F VIII belongs IPSEN
IPSEN
INSPIRATION
Sublicence OBI-1
50M $ in cash or convertible bond
50 M$ + 27,5 % sales
85 M$ = initial investment
85 M$ financing
Shares representing 20% of Ins. equity
 1 member of IPSEN in Board of directors of Inspiration
259 M$ of funding for development and marketing of its portfolio in hemophilia
Until 174 M$
Based on the successful development of OBI-1 & IB1001
1 convertible bond into equity/payment
 IPSEN could hold up to 47% of Inspiration equity!

34. Example of partnership with Inspiration: Advantages2
Example of partnership with Inspiration: Advantages
IPSEN
INSPIRATION
Robust portfolio
Engage in a niche industry
Few competitors
Low risk-taking (payment based on results)
Benefit from the expertise of specialists in hematology
If all goes well, can acquire the entire equity of Inspiration Biopharmaceuticals
Enjoy a worldwide group to implement its products
Addition of OBI-1 in their portfolio
Become the world leader in the field of hemophilia
Thanks to OBI-1, Insp. Portfolio could generate sales exceeding $ 1 billion within 10 years

35. So … 2 Realize partnership permits to IPSEN:
sell products that are not in its field (little knowledge)
engage with partners only if it can make a profit
eventually buy out his partner / no longer care

36. Partnership with Medicis and Galderma2
Partnership with Medicis and Galderma
Botulinum neurotoxin, type A, bought from Octagen.
Therapeutic indications:
hemifacial spasticity
cervical dystonia
blepharospasm
Esthetic indication:
glabellaires wrinkles
Keeps its rights
Market estimated to $ 760 – 800 M
BUT
Not part of Ipsen’s expertise
Partnerships

37. UE, Russia, East Europe, Central Asia, Israël, Liban.2
Partnership with Medicis and Galderma
UE, Russia, East Europe, Central Asia, Israël, Liban.
USA, Canada and Japan
$ 10M
$ 90.1 M
$ 20M
$ 26.5 M
$ 75 M
$ X M
30% of turnover
40% of turnover
$ 2 M
Supplies. Fixed price.
$ 35 M
Supplies. Fixed price.
Min $ 30 M
Selon les termes de cet accord, Medicis a déjà versé à Ipsen la somme de 90,1 millions de dollars et s’est engagé à payer
les sommes supplémentaires suivantes :
26,5 millions de dollars lorsque les différentes étapes cliniques et réglementaires auront été atteintes ;
75,0 millions de dollars lorsque le produit aura été autorisé par la FDA ;
et 2,0 millions de dollars lorsque le produit aura obtenu les autorisations réglementaires au Japon.
De plus, conformément à cet accord et à la suite de l’arrêt des négociations pour les autres territoires, Medicis va dès
maintenant verser à Ipsen la somme supplémentaire de 35 millions de dollars.
$ M
Developpement, distribution and market rights
Developpement, distribution and promotion rights
2006, until 2036
2007, until 2019

38. Partnership with Medicis and Galderma2
Partnership with Medicis and Galderma
Advantages
IPSEN
GALDERMA
MEDICIS
Develop a product which is already well-known as a medecine
No bad surprises, less risky
Be sure to be supplied
Be sure to sell its product for a long period of time
Reach unknown markets through
locally well-known partners

39. 2
Partnership policy
2003
2004
2006
2007
2008
2009
Endocrinology
Taspoglutide (GLP-1 analog, antidiabetic): developpement and marketing
Oncology
Acapodene ( SERM, Prostate Cancer): developpement and marketing in EU
Neurology
Hematology
Primary Care

40. New boss.... New strategy Optimize its primary care portfolio1
Optimize its primary care portfolio
Geographic expansion
Focus on targeted therapeutic areas 2 3

41. Focus on targeted therapies3
Therapeutic areas
% variation
Oncology
1,1%
Endocrinology
26,2%
Neurology
17%
Hematology -
Total
12,6%
Wilde impact of :
≈ 139,2%
of growth
≈ 299,3%
of growth

42. R&D 3 Early commitment, since 1969 More 800 personnes in R&D
About 20% of CA for R&D every year
Currently 20 programs
diversifié et réparti de manière homogène entre les différentes phases cliniques, le por- tefeuille de R&d assure l’avenir des domaines thérapeutiques ciblés du Groupe.
Peptide engineering
Modification through synthesis of derivative of naturally occuring neuropeptide hormones
Protein engineering
Improve the therapeutic properties of naturally occuring proteins through the selective modification of their sequences

43. International knowledge3
International knowledge
4 research centers:
Paris : medicinal chemistry and development
Boston : engineering of peptides
and proteins
Londres : synthesis of steroid hormones
Barcelona : drug formulation

44. Partnership agreements3
Salk institute (USA) : « the Ipsen Life Sciences Program » for proliferative and degenerative diseases.
CEA (France) : for Alzheimer and
Parkinson diseases.
ERINE (Netherland) : therapeutic concepts of endocrinology, diabetes and metabolism disorders.
INSERM : breast, prostate tumors
ERINE : Erasmus Research Institute for NeuroEndocrinology
INSERM : Institut nationale pour la santé et la recherche medicale
CEA commiseriat a lenergie atomique

45. Pipeline 3
Their identity

46. 3 Preclinical Oncology :
Angiomates : anticancer agent, anti-angiogenic
acquisition of Sterix
BIM : Cell signalisation, G-protein signal
for prostate and lung cancer
MSH ... Et ghreline : hormones peptidiques
Cd25 inhibitors phosphatases : regulation of cell cycle
Licencied out to Debiopharm for world exclusive right

47. 3 Preclinical Endocrinology : Growing markets
MSH agonists for the MC4 receptor :
metabolic disorders like obesity
Growing
markets
Ghrelin agonists (BIM28131) : regulation
of food intake and gastro intestinal function
and treatment of cachexia
Inhibitor of 11βHSB : for metabolic disorders
NutropinAp® : treatment of growth failure, new formulation for prolonged release
Life cycle management

48. 3
Phase 1
Oncology :
Elomotecan : cytotoxic agent, advanced metastasic cancer.
Partnership with Roche in dec 2002, but Roche quits in may 2005.

49. 3 Phase 2 Oncology : Endocrinology :
Diflomotecan : topoisomerase inhibitor less SE than other
BN : breast cancer expressing oestrogen receptors
partnership with Biomérieux for diagnosis
Endocrinology :
Bim 23A760 : composé chimerique, premier de sa classe!
IGF-1 and growth hormone : combination therapy for the treatment of idiopathic short stature Combo
BIM 23A760 : somatostatine analog and dopamine agonist for acromegaly and neuroendocrine tumors
Better wide activity with synergy

50. 3 Phase 3 Oncology : Hematology :
Decapeptyl® : combined hormone therapy for premenopausal breast cancer wirh Aromasin® Pfizer Combo
Toremifene® : GTX licence buyout Development of new indications
Decapeptyl 6mois, regulatory review en Europe?
Hematology :
OBI-1 : hemophilia Pig fact VIII

51. Phase 3 3 Endocrinology : Life cycle management Somatuline® Autogel®
Somatuline® Depot®
Increlex® : primary deficit in IGF Global actor in the
growth disorders
Taspoglutide : type 2 diabetes (partnership with Roche)
GLP1, third on the market
Life cycle management
Exemple bieta
GLP1: glucagon like peptide 1

52. 3 Neurology : Research program : new formulation for botulique toxin.
Implant on the world market of Dysport® with Galderma, and Medicis and of Apokin® with Vernalis buyout

53. New authorization in 2009 3 Décapeptyl® 6months : launch in France.
Dysport® : launch in USA for cosmetic and therapeutic indications.
Azzalure® : marketing authorization in Spain, Germany, France and UK, and launch by Galderma.

54. IPSEN gives itself the means of a strong and sustainable growth
Endocrinology
Hematology
Neurology
Oncology
En développant sa présence à travers le monde, notamment aux USA
- En renforcant son portefeuille de molécules dans ses 4 domaines de médecine de spécialité
- En menant une politique active de partenariats et alliancescommerciales
IPSEN gives itself the means of a strong and sustainable growth

55. History of stockmarket

56. IPSEN stockmarket
Consideration of introduction in stockmarket, year of the opening of the capital of the laboratory to the caisse de dépots and paribas affaires industrielles, which then took a participation of 20%
1998
2003
The conditions of market have not been favorable.
Wait until they improve
2005
Initial Public Offering in december

57. Capital social
Dividende par action: 0,60
Dividende par action: 0,66

58. Holding Mayroy * * Participation majoritaire des Beaufour.
Implication des Beaufour
Participation majoritaire des Beaufour.

59. Sales and Income (Before 2002)

60. Sales and Income ( )

61. Changes in Stock Price Number of shares: 84.105.633 .
2005, December 7 : 22,20€ per share
Number of shares:
Always above 22, 20€

62. Conclusion

63. SWOT analysis STRENGHTS WEAKNESSES OPPORTUNITIES THREATS
Independent firm
Technology plateforms very competitives
Strong R&D capabilities
Numerous partnership agreements
Life cycle management
Family decision-making power
WEAKNESSES
Weak sales in primary care
Lack of critical size
OPPORTUNITIES
Establishment of commercial presence in the US
Increasing presence in the emerging markets
A esthetic market : Botulinum toxin A
THREATS
Generics
End of reimbursement of cash cow

64. What do you think about IPSEN?
Catherine : + strong R&D
- leave out of primary care PRODUCTION
Sophie : + strong R&D
+ partnership organisation R&D
Gaelle : + partnership organisation
+ growth DEVPT GALENIQUE
Mélodie : + partnership organisation
+ strategy MARKETING STRATEGIQUE

65. Thanks for your attention
Any questions ?

66. Embauches au sein du groupe

67. Partnership policy
Many partnership to enrich R&D portfolio and expand products range
→ R&D collaboration : Market Ipsen’s products in Japan
→ R&D agreement and acquisition 20% of CA : new technologies
Oct 09 : new agreement SG2000 (anticancer agent, 1st class)
→ Marketing licence for Nisis® & Nisisco®
Jan 09: co-promotion agreement Exforge® in France
→ R&D agreement formulation growth hormone LP
Nombreux partenariats visant à enrichir le portefeuille de R&D et à élargir la gamme de produits:
TEIJIN 2003 POUR COMMERCIALISATION DE MOL IPSEN AU JAPON (collaboration R&D)
SPIROGEN 2003 (BOTECH ANGLAISE POUR ACCEDER A DE NOUVELLE TECHNO) accord de R&D (ipsen acquiert 20% du CA)
oct 09: nvel accord permettant à spirogen de poursuivre dvpmt clinique de l’agent anticancéreux de 1e classe
NOVARTIS 2003 NISIS ET NISICO (COMMERCIALISATION) janv 09: accord copromotion Exforge en Fce (antiHTA)
GENENTECH accord R&D POUR FORMULATION LP HORMONE DE CROISSANCE
AUXILIUM 2004 contrat de licence pour COMMERCIALISATION PAR LE GROUPE DE TESTIM GEL
ROCHE 2006 DEV ET COMMERCIALISATION DU BIM51077 (antidiabétique)
GTx INC 2006 DEV ET COMMER ACAPODENE DANS UE (SERM)
MEDICIS 2006 ET GALDERMA 2007 TOXINE BOTULIQUE
→ marketing licence for Testim® in France
→ Development and marketing BIM 51077
→ development and marketing licence Acapodène® in UE

68. Partnership policy
→ development and marketing licence Toxine botulique (dysport®, Azzalure®)
→ R&D agreement for development of pharmacogenomic tests for growth retardation
→ R&D agreement for development of innovative products in diabete, endocrinology and metabolism
→ R&D agreement for development of diagnostic test in breast cancer
→ co-marketing licence Adrovance® TM in France
CELERA 2006 accord R&D DEV TEST PHCOGENOMIQUE RETARD CROISSCE
2007 ALLIANCE AVEC CENTRE MEDICAL ERASMUS DE ROTTERDAM POUR DEV DES PRODUITS INNOVANT EN ENDOCRINO DIABETE METABOLISME
BIOMERIEUX 2007 ACCORD POUR LE DEV TEST DIAGNOSTIC CANCER SEIN
MSD 2007 ACCORD CO-MARKETING ADROVANCE TM en France (ostéoporose post ménop)
TERCICA 2008 accord définitif de fusion (juill 06: accord licence relatif à Somatuline® Autogel®
DEBIOPHARM 2008 COMMERCIALISATION TRIPTORELINE SOUS PLUSIEURS NOMS MARQUE (Salvatyl LP) 1e accord 1983: fabrique et commercialise Decapeptyl
VERNALIS 2008 ACQUISITION FINALE DROITS DE APOKYN (parkinson): équipe commerciale dédiée et expérimentée en neuro
OCTAGEN 2008 accord d’achat: Ipsen récupère tous les actifs liés à OBI-1 (hémophilie)
→ definitive merger agreement
july 06: licence agreement Somatuline® Autogel®
→ marketing licence Triptoreline under several brandnames (Salvatyl LP®)
1983: 1st development and marketing licence Decapeptyl®
→ final purchase rights Apokyn® (PK)

69. Partnership policy
→ purchase agreement, recovery of all actives related with OBI-1
→ development and marketing licence BLI-800 : colic washing before coloscopy
→ exclusive right of licence for Menarini Adenuric®
Le 9 octobre 2009, le Groupe et Braintree ont annoncé la signature d’un accord pour les droits exclusifs de distribution, de commercialisation et de fabrication d’une formulation issue de la recherche de Braintree (BLI-800) dans le domaine du lavage colique avant coloscopie, la meilleure procédure diagnostique pour le dépistage du cancer colorectal.
Le 20 octobre 2009, Le Groupe a annoncé la conclusion d’un accord aux termes duquel Ipsen accorde au Groupe Menarini les droits de licence exclusifs pour Adenuric® (febuxostat) dans 41 pays en concervant les droits de co-promotion d’Adenuric® en France. Adenuric® a reçu une autorisation de mise sur le marché dans l’Union européenne le 21 avril Adenuric® 80 mg et 120mg (comprimés) est indiqué dans le traitement de l’hyperuricémie chronique après existence/occurrence d’un dépôt d’urate (incluant des antécédents ou la présence de tophus et/ou d’arthrite goutteuse). En 2003, Teijin Pharma Limited (Tokyo), qui a découvert le febuxostat, avait accordé à Ipsen les droits exclusifs de développement et de commercialisation d’Adenuric® en Europe.